Investing.com - Oragenics reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Oragenics announced earnings per share of $-0.0300 on revenue of $86.05K. Analysts polled by Investing.com anticipated EPS of $-0.0500 on revenue of $0.00.
Oragenics shares are down 57.42% from the beginning of the year and are trading at $0.1899 , down-from-52-week-high.
Oragenics follows other major Healthcare sector earnings this month
Oragenics's report follows an earnings beat by Eli Lilly on November 1, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on October 28 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar